Brian Mueller - 30 Apr 2021 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
30 Apr 2021
Transactions value $
-$322,690
Form type
4
Filing time
11 May 2021, 19:42:54 UTC
Next filing
30 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21.3K +341 +1.1% $62.41 31.4K 30 Apr 2021 Direct F1
transaction BMRN Common Stock Options Exercise $189K +6.71K +21.4% $28.23 38.1K 07 May 2021 Direct F2
transaction BMRN Common Stock Sale -$533K -6.71K -17.62% $79.50 31.4K 07 May 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -6.71K -100% $0.00* 0 07 May 2021 Common Stock 6.71K $28.23 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on January 29, 2021.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.